Skip to main content

Table 1 Baseline characteristics of participants according to the progression of glucose metabolism disturbance.

From: Predictive factors of non-deterioration of glucose tolerance following a 2-year behavioral intervention

  Progressors
n = 72
Non-progressors
n = 182
p
Women 44 (61) 104 (57) 0.56
Age ≥ 60 years 42 (58) 84 (46) 0.08
Increased BMI 36 (50) 104 (57.1) 0.28
Abdominal obesity 45 (62.5) 104 (57.1) 0.46
Hypertension 31 (43) 77 (43.1) 0.91
Glucose metabolism    
   Normal 47 (65.3) 41 (22.5) <0.001
   IFG or IGT 25 (34.7) 141 (77.5)  
Dyslipidemia 55 (76.4) 151 (83.0) 0.42
Insulin (uIU/mL)    
   < 2.3 23 (41.1) 51 (30.0) 0.22
   ≥ 2.3 to < 4.8 23 (41.1) 73 (42.9)  
   ≥ 4.8 10 (17.9) 46 (27.1)  
Adiponectin (ng/mL)    
   < 5.3 20 (33.2) 58 (33.9) 0.40
   ≥ 5.3 to < 8.8 17 (28.3) 62 (36.3)  
   ≥ 8.8 23 (38.3) 51 (29.8)  
C-reactive protein (mg/dL)    
   < 0.04 11 (18.6) 49 (28.7) 0.02
   ≥ 0.04 to < 0.14 18 (30.5) 70 (40.9)  
   ≥ 0.14 30 (50.8) 52 (30.4)  
Interleukin-6 (pg/dL)    
   < 1.8 14 (25.0) 51 (30.2) 0.76
   ≥ 1.8 to < 2.8 21 (37.5) 58 (34.3)  
   ≥ 2.8 21 (37.5) 60 (35.5)  
Tumor necrosis factor-α (pg/dL)    
   < 3.6 18 (32.1) 53 (31.4) 0.98
   ≥ 3.6 to < 6.2 20 (35.7) 59 (34.9)  
   ≥ 6.2 18 (32.1) 57 (33.7)  
  1. Data expressed in number of individuals and percentages in parenthesis.
  2. p value from chi-square test.
  3. BMI, body mass index
  4. IFG, impaired fasting glucose
  5. IGT, impaired glucose tolerance